The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome
Open accessAbstract
Background & Aims: Irritable Bowel Syndrome (IBS) patients still require effective treatment. The anti-inflammatory property of curcumin and the antispasmodic and carminative effect of fennel suggests that combination of these nutraceutical compounds would be useful in functional bowel disorders including IBS. We assessed the efficacy and tolerability of a combination of curcumin and fennel essential oil (CU-FEO) in IBS symptoms relief. Methods: 121 patients with mild-to-moderate symptoms of IBS defined by an Irritable Bowel Syndrome- symptom severity score (IBS-SSS) 100-300 and abdominal pain score 30-70 on a 100 mm Visual Analogue Scale (VAS), were randomly assigned to CU-FEO or placebo (2 capsules b.d. for 30 days). Primary endpoint was the mean decrease of IBS-SSS at the end of the treatment corrected for the mean baseline score (relative decrease). The impact of the treatment on quality of life was assessed through IBS-QoL questionnaire. Results: CU-FEO was safe, well-tolerated and induced symptom relief in patients with IBS; a significant decrease in the mean relative IBS-SSS was observed after 30 days of treatment (50.05 ± 28.85% vs 26.12 ± 30.62%, P<0.001). This result matched the reduction of abdominal pain and all the other symptoms of IBS-SSS. The percentage of symptom-free patients was significantly higher in the CU-FEO than in the placebo group (25.9% vs. 6.8%, P = 0.005). All domains of IBS-QoL improved consistently. Conclusion: CU-FEO significantly improved symptoms and quality of life in IBS patients over 30 days. Abbreviations: AEs: adverse events; CU-FEO: Curcumin-Fennel Essential Oil; GI: gastrointestinal; IBS: irritable bowel syndrome; IBS-D: irritable bowel syndrome-diarrhea; IBS-C: irritable bowel syndrome-constipation; IBS-SSS: Irritable Bowel Syndrome – symptom severity score; NF-kB: nuclear factor-κB; QoL: quality of life; UC: ulcerative colitis; VAS, Visual Analogue Scale.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A randomized, placebo-controlled trial assessing the efficacy and tolerability of a combination of curcumin and fennel essential oil, named CU-FEO, in 121 patients with mild-to-moderate IBS observed a reduction in abdominal pain and other IBS symptoms, assessed as a reduction in IBS-SSS, as well as an improvement of general quality of life after 30 days of treatment [83].”
From Natural Remedies for Irritable Bowel Syndrome: A Comprehensive Review of Herbal-Based Therapies (2025) · cites this paper as [83]
In the citing paper
“In conclusion, fennel essential oil and its bioactive components may alleviate IBS symptoms by relaxing intestinal smooth muscle, reducing visceral hypersensitivity through anti-inflammatory and neuro-modulatory effects, and promoting a healthier gut microbiota balance [83].”
From Natural Remedies for Irritable Bowel Syndrome: A Comprehensive Review of Herbal-Based Therapies (2025) · cites this paper as [83]
In the citing paper
“Additionally, certain herbal treatments, like combinations of curcumin and fennel oil, have been demonstrated to induce improvements in validated scores assessing IBS symptoms and quality of life.”
From Natural Remedies for Irritable Bowel Syndrome: A Comprehensive Review of Herbal-Based Therapies (2025) · cites this paper as [83]
In the citing paper
“It also appears safe and well-tolerated, with no adverse events reported in the available trials.”
From A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS) (2018) · cites this paper as [28]
In the citing paper
“It was encouraging that curcumin had demonstrated positive effects in the other two placebo-controlled trials [24,28], which recruited male and female patients with at least moderate symptom severity (IBS-SSS ranging from 250 to 300).”
From A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS) (2018) · cites this paper as [28]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials
Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013) · The AAPS Journal · doi:10.1208/s12248-012-9432-8 · Cited by 2,110
Burden of Gastrointestinal Disease in the United States: 2012 Update
Peery, A. F., Dellon, E. S., Lund, J. L., Crockett, S. D., McGowan, C., Bulsiewicz, W. J., Gangarosa, L. M., Thiny, M. T., Stizenberg, K., Morgan, D. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.08.002 · Cited by 2,010
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Jobin, C., Bradham, C. A., Russo, M. P., Juma, B., Narula, A. S., Brenner, D. A., & Sartor, R. B. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.6.3474 · Cited by 834
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761 · cited 1×
“The IBS QoL questionnaire [31] was used as a self-reported measure to assess the impact of the treatment on QoL and completed at baseline and at the end of treatment.”
MethodCurcumin: Getting Back to the Roots
SHISHODIA, S., SETHI, G., & AGGARWAL, B. B. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1352.010 · Cited by 715
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 670
Hanai, H., Iida, T., Takeuchi, K., Watanabe, F., Maruyama, Y., Andoh, A., Tsujikawa, T., Fujiyama, Y., Mitsuyama, K., Sata, M., et al. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.08.008 · Cited by 569
DROSSMAN, D. A., CHEY, W. D., JOHANSON, J. F., FASS, R., SCOTT, C., PANAS, R., & UENO, R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03881.x · Cited by 399 · cited 1×
“Definitive treatment options are still missing in IBS patients with either diarrhea or constipation and might include from time to time dietary modification, laxatives, lubiproston, linaclotide, antidiarrhoeals, alosetron, rifaximin, eluxadoline [2-5].”
BackgroundComparative Absorption of a Standardized Curcuminoid Mixture and Its Lecithin Formulation
Cuomo, J., Appendino, G., Dern, A. S., Schneider, E., McKinnon, T. P., Brown, M. J., Togni, S., & Dixon, B. M. (2011) · Journal of Natural Products · doi:10.1021/np1007262 · Cited by 339
Eluxadoline for Irritable Bowel Syndrome with Diarrhea
Lembo, A. J., Lacy, B. E., Zuckerman, M. J., Schey, R., Dove, L. S., Andrae, D. A., Davenport, J. M., McIntyre, G., Lopez, R., Turner, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505180 · Cited by 334 · cited 1×
“Definitive treatment options are still missing in IBS patients with either diarrhea or constipation and might include from time to time dietary modification, laxatives, lubiproston, linaclotide, antidiarrhoeals, alosetron, rifaximin, eluxadoline [2-5].”
BackgroundUkil, A., Maity, S., Karmakar, S., Datta, N., Vedasiromoni, J. R., & Das, P. K. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705241 · Cited by 269
Curcumin prevents and ameliorates trinitrobenzene sulfonic acid–induced colitis in mice
Sugimoto, K., Hanai, H., Tozawa, K., Aoshi, T., Uchijima, M., Nagata, T., & Koide, Y. (2002) · Gastroenterology · doi:10.1053/gast.2002.37050 · Cited by 262
Ostad, S. N., Soodi, M., Shariffzadeh, M., Khorshidi, N., & Marzban, H. (2001) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(01)00249-5 · Cited by 173
A Systematic Review of Alternative Therapies in the Irritable Bowel Syndrome
Spanier, J., Howden, C. W., & Jones, M. P. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.3.265 · Cited by 163
Herbal medicines for treatment of irritable bowel syndrome
Liu, J., Yang, M., Liu, Y., Wei, M. L., & Grimsgaard, S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004116.pub2 · Cited by 134
Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis
Lubbad, A., Oriowo, M. A., & Khan, I. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-9949-4 · Cited by 134
Bundy, R., Walker, A. F., Middleton, R. W., & Booth, J. (2004) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2004.10.1015 · Cited by 131
Predictors of Patient-Assessed Illness Severity in Irritable Bowel Syndrome
Spiegel, B. M. R., Strickland, A., Naliboff, B. D., Mayer, E. A., & Chang, L. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01997.x · Cited by 126
Curcumin Prevents the Development of Dextran Sulfate Sodium (DSS)-Induced Experimental Colitis
Deguchi, Y., Andoh, A., Inatomi, O., Yagi, Y., Bamba, S., Araki, Y., Hata, K., Tsujikawa, T., & Fujiyama, Y. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9138-9 · Cited by 119
Epstein, J., Docena, G., MacDonald, T. T., & Sanderson, I. R. (2010) · British Journal of Nutrition · doi:10.1017/s0007114509992510 · Cited by 111
Therapeutic potential of curcumin in gastrointestinal diseases
Langhans, S. A. (2011) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v2.i1.1 · Cited by 108
Curcumin: The potential for efficacy in gastrointestinal diseases
Irving, G. R. B., Karmokar, A., Berry, D. P., Brown, K., & Steward, W. P. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.09.005 · Cited by 104
Modulation of neutrophil motility by curcumin: Implications for inflammatory bowel disease
Larmonier, C. B., Midura‐Kiela, M. T., Ramalingam, R., Laubitz, D., Janikashvili, N., Larmonier, N., Ghishan, F. K., & Kiela, P. R. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21391 · Cited by 104
Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis
Zhang, M., Deng, C., Zheng, J., & Jian, X. I. A. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00322.x · Cited by 81
Billerey-Larmonier, C., Uno, J. K., Larmonier, N., Midura, A. J., Timmermann, B. N., Ghishan, F. K., & Kiela, P. R. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20348 · Cited by 80
Effect of Dietary Turmeric on Breath Hydrogen
Shimouchi, A., Nose, K., Takaoka, M., Hayashi, H., & Kondo, T. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0550-1 · Cited by 70
Martelli, L., Ragazzi, E., Mario, F. D., Martelli, M., Castagliuolo, I., Maschio, M. D., Palù, G., Maschietto, M., Scorzeto, M., Vassanelli, S., et al. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.00928.x · Cited by 67
Yoncheva, K., Kamenova, K., Perperieva, T., Hadjimitova, V. A., Donchev, P., Kaloyanov, K. A., Konstantinov, S., Kondeva-Burdina, M., Tzankova, V. I., & Petrov, P. D. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.05.057 · Cited by 63
Possible mechanism(s) for relaxant effects of Foeniculum vulgare on guinea pig tracheal chains.
Boskabady, M. H., Khatami, A., & Nazari, A. (2004) · PubMed · Cited by 53
Curcumin loaded pH-sensitive hybrid lipid/block copolymer nanosized drug delivery systems
Jelezova, I., Drakalska, E., Momekova, D. B., Shalimova, N., Momekov, G., Konstantinov, S., Rangelov, S., & Pispas, S. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.07.005 · Cited by 52
Ishihara, S., Tada, Y., Fukuba, N., Oka, A., Kusunoki, R., Mishima, Y., Oshima, N., Moriyama, I., Yuki, T., Kawashima, K., et al. (2013) · Digestion · doi:10.1159/000350054 · Cited by 52
Aldini, R., Budriesi, R., Roda, G., Micucci, M., Ioan, P., D’Errico, A., Sartini, A., Guidetti, E., Marocchi, M., Cevenini, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044650 · Cited by 46
Antineoplastic and Anticlastogenic Properties of Curcumin
Alaikov, T., Konstantinov, S., Tzanova, T., DINEV, K., Topashka-Ancheva, M. N., & Berger, M. R. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1397.039 · Cited by 37
Yosifov, D. Y., Kaloyanov, K. A., Guenova, M. L., Prisadashka, K., Balabanova, M. B., Berger, M. R., & Konstantinov, S. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.10.011 · Cited by 34
Placebo effect in patients with irritable bowel syndrome
Lu, C., & Chang, F. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06651.x · Cited by 34
Current and emerging therapies for the management of functional gastrointestinal disorders
Craig, O. F., & Quigley, E. M. M. (2010) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310389507 · Cited by 14
Foeniculum vulgare therapy in irritable bowel syndrome
Amjad, H., & Jafary, H. A. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02633.x · Cited by 14
Guenova, M. L., Michova, A., Balatzenko, G. N., Yosifov, D. Y., Stoyanov, N., Taskov, H. B., Berger, M. R., & Konstantinov, S. (2012) · Hematology · doi:10.1179/102453312x13376952196296 · Cited by 4
Cited by
Peng, Y., Ao, M., BaoHua, D., Jiang, Y., Yu, L., Chen, Z., Hu, C.-J., & Xu, R. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s327378 · Cited by 933
Cellular and molecular mechanisms of curcumin in prevention and treatment of disease
Patel, S. S., Acharya, A., Ray, R. S., Agrawal, R. K., Raghuwanshi, R., & Jain, P. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1552244 · Cited by 534
Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?
Hegde, M., Girisa, S., BharathwajChetty, B., Vishwa, R., & Kunnumakkara, A. B. (2023) · ACS Omega · doi:10.1021/acsomega.2c07326 · Cited by 346
Kunnumakkara, A. B., Hegde, M., Parama, D., Girisa, S., Kumar, A., Daimary, U. D., Garodia, P., Yenisetti, S. C., Oommen, O. V., & Aggarwal, B. B. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00012 · Cited by 229
Is curcumin bioavailability a problem in humans: lessons from clinical trials
Kunnumakkara, A. B., Harsha, C., Banik, K., Vikkurthi, R., Sailo, B. L., Bordoloi, D., Gupta, S. C., & Aggarwal, B. B. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1650914 · Cited by 217
Metadata
- Authors
- Portincasa, P., Bonfrate, L., Scribano, M., Kohn, A., Caporaso, N., Festi, D., Campanale, M. C., Di Rienzo, T., Guarino, M., Taddia, M., Fogli, M. V., Grimaldi, M., & Gasbarrini, A.
- Affiliations
- University of Bari Aldo Moro (IT)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- Federico II University Hospital (IT)
- University of Bologna (IT)
- Università Cattolica del Sacro Cuore (IT)
- ORCID
- Venue
- Journal of Gastrointestinal and Liver Diseases
- Published
- 2016-06-01
- Volume
- 25
- Issue
- 2
- Pages
- 151-157
- ISSN
- 1221-4167 (ISSN-L)
- 1842-1121
- 1841-8724
- OpenAlex
- W2469611409
- Cited by
- 109
- References
- 42
- Citations by year
- 2026: 4 · 2025: 17 · 2024: 18 · 2023: 15 · 2022: 12 · 2021: 8 · 2020: 9 · 2019: 11 · 2018: 6 · 2017: 8
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Journal of Gastrointestinal and Liver Diseases (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Curcumin's Biomedical Applications
- Keywords
- irritable bowel syndrome, curcumin, fennel essential oil, nutraceutical combination, symptom severity, quality of life, abdominal pain, IBS-SSS, IBS-QOL, anti-inflammatory agents, antispasmodic agents, functional bowel disorders
- MeSH terms
- Adolescent, Adult, Aged, Anti-Inflammatory Agents, Curcumin, Double-Blind Method, Drug Combinations, Female, Gastrointestinal Agents, Humans, Italy, Male, Phytotherapy, Middle Aged, Oils, Volatile, Plant Oils, Plants, Medicinal, Quality of Life, Surveys and Questionnaires, Remission Induction, Severity of Illness Index, Time Factors, Treatment Outcome, Foeniculum, Irritable Bowel Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
